We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Antipsychotics and Metabolic Syndrome

This study has suspended participant recruitment.
(this study has not finding place)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00636753
First Posted: March 14, 2008
Last Update Posted: July 30, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Glostrup University Hospital, Copenhagen
  Purpose
The purpose of the study is to determine whether antipsychotic treatment is influence psychiatric patients due to endocrine and metabolic status and quality of life.

Condition
Metabolic Syndrome

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Glostrup University Hospital, Copenhagen:

Biospecimen Retention:   None Retained
whole blood, serum/plasma

Estimated Enrollment: 60
Study Start Date: September 2008
Estimated Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
schizophrenic patients
2
controls

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients with debut of schizophrenia, controls from database
Criteria

Inclusion Criteria:

  • Gender male
  • Age 18-45
  • Debut drug-naive schizophrenics,
  • Caucasians
  • Consent given to take part in the project

Exclusion Criteria:

  • Compliance-problems
  • Major lung-/kidney/hart/lever disorders
  • Abuse of alcohol/drugs
  • Diabetes 1 and 2
  • Antihypertensive
  • Anticholesterol-reducing medication
  • Patients under duress
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00636753


Locations
Denmark
Psychiatric Center Glostrup
Copenhagen, Nordre Ringvej 28-69, Glostrup, Denmark, 2600
Psychiatric Center Glostrup
Nordre Ringvej 28-69, Glostrup, Denmark, 2600
Sponsors and Collaborators
Glostrup University Hospital, Copenhagen
  More Information

Responsible Party: dr.med., centerchef Henrik Lublin, Psychiatric Center Glostrup
ClinicalTrials.gov Identifier: NCT00636753     History of Changes
Other Study ID Numbers: HC-2007-0070
First Submitted: March 7, 2008
First Posted: March 14, 2008
Last Update Posted: July 30, 2010
Last Verified: July 2010

Keywords provided by Glostrup University Hospital, Copenhagen:
Metabolic and endocrine changes in schizophrenic patients by antipsychotics treatment.

Additional relevant MeSH terms:
Syndrome
Metabolic Syndrome X
Disease
Pathologic Processes
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs